Alkermes plc(ALKS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:15 PM ET (Korea 9/12 05:15)
Full metrics table
| Index | RUT | P/E | 119.4 | EPS (ttm) | 0.39 | Insider Own | 2.98% | Shs Outstand | 167.5M | Perf Week | -1.94% |
| Market Cap | 7.71B | Forward P/E | 67.49 | EPS next Y | 242.28% | Insider Trans | -2.66% | Shs Float | 162.8M | Perf Month | -8.57% |
| Enterprise Value | 8.63B | PEG | - | EPS next Q | -0.04 | Inst Own | 105.31% | Short Float | 9.04% | Perf Quarter | 2.34% |
| Income | 0.07B | P/S | 4.62 | EPS this Y | -133.48% | Inst Trans | -0.6% | Short Ratio | 7.78 | Perf Half Y | 66.32% |
| Sales | 1.67B | P/B | 4.26 | EPS next 5Y | -4.68% | ROA | 1.99% | Short Interest | 14.72M | Perf YTD | 64.3% |
| Book/sh | 10.79 | P/C | 11.75 | EPS past 3/5Y | - | ROE | 3.85% | 52W High | -17.42% ($55.67) | Perf Year | 65.9% |
| Cash/sh | 3.91 | P/FCF | 34.79 | Sales past 3/5Y | 9.9% 7.28% | ROIC | 1.98% | 52W Low | 74.13% ($26.40) | Perf 3Y | 67.52% |
| Dividend Est. | - | EV/EBITDA | 42.03 | EPS Y/Y TTM | -81.14% | Gross Margin | 82.13% | Volatility(W/M) | 3.03% 2.94% | Perf 5Y | 62.03% |
| Dividend TTM | - | EV/Sales | 5.17 | Sales Y/Y TTM | 10.79% | Oper. Margin | 8.62% | ATR (14) | 1.45 | Perf 10Y | 8.97% |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | EPS Q/Q | -99.44% | Profit Margin | 3.97% | RSI (14) | 37.85 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.3 | Sales Q/Q | 26.97% | SMA20 | -3.86% ($47.82) | Beta | 0.31 | Target Price | $55.98 |
| Payout | - | Debt/Eq | 0.87 | Earnings | 2026/7/28 | SMA50 | -8.05% ($49.99) | Rel Volume | 0.65 | Prev Close | $46.11 |
| Employees | 2050 | LT Debt/Eq | 0.85 | EPS/Sales Surpr. | 100% 8.45% | SMA200 | 20.81% ($38.05) | Avg Volume(3M) | 1.89M | Price | $45.97 |
| IPO | 1991/7/16 | Option/Short | Yes/Yes | Trades | 13242 | Volume | 1,222,025 | Change | -0.3% |
Company
ALKS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 This is a commercial-stage biopharmaceutical company that develops and sells treatments for central nervous system (CNS) disorders. It generates revenue and profit by selling therapies for neurological and psychiatric conditions such as schizophrenia, bipolar disorder, and addiction, while also advancing a pipeline that includes treatments for narcolepsy and other indications, making it a healthcare stock whose performance is tied to both its revenue base and pipeline progress.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
ALKS makes money exceptionally well
8.62% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -133.5% this year.
Tap to view numbers
The price looks about right
Trading at 119.4 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +67.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 105.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MEDX 0.06%
SBIO 0.04%
PSIL 0.04%
FBT 0.04%
IBRN 0.04%It ranks #4 in the industry
Based on market cap of $8B.
ALKS $8B PER 119.4
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is ALKS?
ALKS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ALKS?
The market cap of ALKS is approximately $7.7B, ranking 1,094 within its sector.
What is the P/E ratio of ALKS?
ALKS has a P/E ratio of approximately 119.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ALKS?
ALKS has recorded a 52-week high of $55.67 and a low of $26.40.
